Effect of statin treatment on short term mortality after pneumonia episode: cohort study
- PMID: 21471172
- PMCID: PMC3071610
- DOI: 10.1136/bmj.d1642
Effect of statin treatment on short term mortality after pneumonia episode: cohort study
Abstract
Objective: To determine whether statins protect against all cause mortality after a diagnosis of pneumonia.
Design: Cohort study using propensity score based method to control for differences between people prescribed and not prescribed statins.
Setting: United Kingdom Health Improvement Network database, which contains electronic primary care medical records of more than six million patients.
Participants: Every patient starting a statin between 1995 and 2006 (129,288) matched with up to five non-statin users (n = 600,241); 9073 patients had a recorded diagnosis of pneumonia, of whom 1398 were using a statin.
Main outcome measure: All cause mortality within six months of diagnosis of pneumonia.
Results: Among users and non-users of statins with comparable propensity scores, 95/942 users and 686/3615 non-users died on the day that pneumonia was diagnosed. In the following six month period, 109/847 statin users died compared with 578/2927 non-users, giving an adjusted hazard ratio of 0.67 (0.49 to 0.91). If these observed benefits translated into clinical practice, 15 patients would need to be treated with a statin for six months after pneumonia to prevent one death.
Conclusions: Compared with people who were not taking statins, the risk of dying in the six month period after pneumonia was substantially lower among people who were already established on long term statin treatment when the pneumonia occurred. Whether some or all of this protective effect would be obtained if statin treatment begins when a patient first develops pneumonia is not known. However, given that statins are cheap, safe, and well tolerated, a clinical trial in which people with pneumonia are randomised to a short period of statin treatment is warranted.
Conflict of interest statement
Competing interests: All authors have completed the Unified Competing Interest form at
Figures
Comment in
-
Statins and pneumonia.BMJ. 2011 Apr 6;342:d1907. doi: 10.1136/bmj.d1907. BMJ. 2011. PMID: 21471176 No abstract available.
-
Statins and pneumonia. Beware statins with macrolides.BMJ. 2011 May 3;342:d2703. doi: 10.1136/bmj.d2703. BMJ. 2011. PMID: 21540266 No abstract available.
Similar articles
-
Association of statin use with risk and outcome of acute kidney injury in community-acquired pneumonia.Clin J Am Soc Nephrol. 2012 Jun;7(6):895-905. doi: 10.2215/CJN.07100711. Epub 2012 Mar 29. Clin J Am Soc Nephrol. 2012. PMID: 22461537 Free PMC article.
-
The effect of statins on influenza-like illness morbidity and mortality.Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):63-70. doi: 10.1002/pds.4112. Epub 2016 Sep 30. Pharmacoepidemiol Drug Saf. 2017. PMID: 27686457
-
The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort.Pharmacoepidemiol Drug Saf. 2009 Aug;18(8):697-703. doi: 10.1002/pds.1769. Pharmacoepidemiol Drug Saf. 2009. PMID: 19455553
-
Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.Cochrane Database Syst Rev. 2013 Jul 3;2013(7):CD009971. doi: 10.1002/14651858.CD009971.pub2. Cochrane Database Syst Rev. 2013. PMID: 23824754 Free PMC article. Review.
-
Beneficial effects of statins on outcomes in pneumonia: a systematic review and meta-analysis.Eur Rev Med Pharmacol Sci. 2014 Aug;18(16):2294-305. Eur Rev Med Pharmacol Sci. 2014. PMID: 25219829 Review.
Cited by
-
Interaction of Glycemic Control and Statin Use on Diabetes-Tuberculosis Treatment Outcome: A Nested Case-Control Study.Can J Infect Dis Med Microbiol. 2024 Jun 20;2024:8675248. doi: 10.1155/2024/8675248. eCollection 2024. Can J Infect Dis Med Microbiol. 2024. PMID: 38938548 Free PMC article.
-
Cardiovascular disease and COVID-19, a deadly combination: A review about direct and indirect impact of a pandemic.World J Clin Cases. 2022 Sep 26;10(27):9556-9572. doi: 10.12998/wjcc.v10.i27.9556. World J Clin Cases. 2022. PMID: 36186196 Free PMC article. Review.
-
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.Cardiovasc Res. 2022 Jun 22;118(7):1618-1666. doi: 10.1093/cvr/cvab343. Cardiovasc Res. 2022. PMID: 34864876 Free PMC article. Review.
-
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.Eur Heart J. 2022 Mar 14;43(11):1059-1103. doi: 10.1093/eurheartj/ehab697. Eur Heart J. 2022. PMID: 34791154 Free PMC article. Review.
-
Association of Pre-Admission Statin Use With Reduced In-Hospital Mortality in COVID-19.Am J Med Sci. 2021 Jun;361(6):725-730. doi: 10.1016/j.amjms.2021.03.001. Epub 2021 Mar 2. Am J Med Sci. 2021. PMID: 33667433 Free PMC article.
References
-
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. - PubMed
-
- Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical